TrialClinical lymphoma, myeloma & leukemia2018

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.

John M Burke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.